BOTHELL, Wash., June 1 /PRNewswire-FirstCall/ -- Helix BioMedix (HXBM.OB),
a developer of synthetic bioactive peptides, today announced the final results
of its warrant exchange, which expired at 9:00 a.m. New York Time, on May 31,
2005. The Company commenced the exchange offer on March 1, 2005 to exchange up
to 6,216,700 warrants to purchase shares of common stock. Based on the final
count by the U.S. Stock Transfer Corporation, 5,458,425 warrants to purchase
shares of common stock were properly tendered and not withdrawn in exchange
for shares of common stock of the Company. The aggregate shares of common
stock purchased by holders of existing warrant shares equaled 4,946,662, and
the aggregate to the Company from the proceeds of the exchange offer,
including fees and expenses associated with the exchange offer, is
approximately $1,511,373.50. As a result of the completion of the exchange
offer, the Company has approximately 20,158,193 million shares of common stock
outstanding.
About Helix BioMedix
Helix BioMedix, Inc. is an early-stage biotechnology company that has a
portfolio of issued patents that covers six distinct classes of peptides,
covering over 100,000 unique peptide sequences. The company's mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties of
these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on the
development of selected peptides as topical anti-infectives and in wound
healing. Non-pharmaceutical applications being pursued by Helix BioMedix
include adjuvants for cosmetics/cosmeceuticals, personal care, plant health,
animal health and wide-spectrum biocides. More information about the company
and its proprietary peptides can be found on the company's website at
http://www.helixbiomedix.com.
Contact:
Helix BioMedix, Inc.
David Kirske, 425-402-8400
dkirske@helixbiomedix.com
or
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
David Kirske of Helix BioMedix, Inc.,
+1-425-402-8400 or dkirske@helixbiomedix.com; or Investor
Relations: Alison Ziegler of Cameron Associates, +1-212-554-5469
or alison@cameronassoc.com, for Helix BioMedix, Inc.
|
